SUNNYVALE, Calif., July 11, 2012 (GLOBE NEWSWIRE) -- Amarantus BioSciences Inc. (OTCBB:AMBS), a California-based biotechnology company focused on the development of a therapeutic protein known as MANF, announced today that TomorrowsBlueChips.com has profiled it in a 9-page research report that can be found directly on the web site under its Research section: http://tomorrowsbluechips.com/research/
The report's analysis states, "Amarantus is now exposed to two global markets: Parkinson's and Traumatic Brain Injury." It adds that "Amarantus is interested in partnering opportunities for its product candidates that will allow development of adjunct-products that will address diseases caused by poorly served biological pathways. The company aims to generate revenues through collecting up-front and milestone payments as its candidates advance through pre-clinical and clinical development, and royalties upon commercialization."
The report also notes a round of buyouts that occurred in 2007-2008 within the industry. "The most extreme example includes GlaxoSmithKline's (GSK) $57M buyout of Genelabs (GNLB) for an astounding 400%+ premium for the latter's hepatitis C clinical development assets."
About Amarantus BioSciences Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company that was founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.
About TomorrowsBlueChips.com
TomorrowsBlueChips.com distributes research reports, press releases, and other news compiled from outside sources.
TBC is a subsidiary of Seraphim Strategies LLC. TBC is an internet stock market site featuring emerging growth companies and focuses on low-priced stocks that appear to have significant upside potential. For more information about Seraphim Strategies LLC and TBC, visit them on the web at www.tomorrowsbluechips.com. Our disclaimer can be viewed at www.tomorrowsbluechips.com/disclaimer/.
Safe Harbor Statement:
This contains such "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements in connection with any discussion of future operating or financial performance are identified by use of words such as "may," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning. Such statements are based on our expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements.
Any statements that express or involve predictions, expectations, plans, beliefs, objectives, projections, future events, goals, or performance may be forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, intense competition, adverse economic conditions, termination of contracts or agreements, inadequate capital, lack of meaningful research results, inability to carry out research and development plans, loss of key personnel, and other risks detailed in the reports filed by the Securities and Exchange Commission by companies that are featured on our properties.
In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this website or in any document accessible from this website might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this posting or the date of the document(s) accessible from this website. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.
Readers should consult with their own professional investment, tax and portfolio advisors before making any investment decision and should independently verify all information herein. More complete information about any of the companies mentioned in this periodical is available from the website of the Securities and Exchange Commission, at http://www.sec.gov , and copies of their filings may be read without charge and copies obtained at prescribed rates from the public reference facilities of the Commission, at 450 Fifth Street, NW, Washington, DC 20549.
For more information, contact us at info@seraphimstrategies.com
Contact:
Seraphim Strategies
Lou Levenstein
727.489.9939
This information was brought to you by Cision http://www.cisionwire.com
http://www.cisionwire.com/amarantus-bioscience/r/amarantus-biosciences-announces-the-release-of-research-report-by-tomorrowsbluechips-com,c9283408